Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

Publication Date: April 19, 2022

Key Points

Key Points

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status.

Diagnosis

...agnosis...

...ER-positive, HER2-negative Breast Cancer...

...(21-gene recurrence score)...

...n 1.1If a patient has node-negative breast cance...

...ommendation 1.2In the group of patie...

...mendation 1.3In the group of patie...

...1.4If a patient is postmenopausal and ha...

...on 1.5In the group of patients in Re...

...ion 1.6If a patient is premenopausal and has nod...

...ndation 1.7If a patient has node-positive bre...

...maPrint (70-gene sign...

Recommendation 1.8If a patient is ol...

...dation 1.9If a patient is 50 years of ag...

...1.10If a patient has low clinical risk, regar...

...commendation 1.11If a patient has node-po...

...ct (12-gene risk score)...

...n 1.12If a patient is postmenopausal and has bre...

...1.13If a patient is premenopausal...

...commendation 1.14If a patient has bre...

...signa (PAM50...

...dation 1.15If a patient is postmenopausal and h...

...mendation 1.16If a patient is premenop...

...mmendation 1.17If a patient is postmenopaus...

...ion 1.18If a patient has node-positive breast ca...

...mmostrat...

...re is insufficient evidence to rec...

...ancer Index (BCI)...

...t has ER-positive, HER2-negative, node-neg...

...tient has ER-positive, HER2-negative, node-p...

...i67

...ommendation 1.19If a patient is pos...

...ecommendation 1.20If a patient is postmenopausal a...

...n 1.21Despite the limitations associat...

...mmunohistochemistry 4 (...

...ndation 1.22If a patient has node-ne...

...PA and PAI-...

...a patient has ER-positive, HER2-negative (node-...

...s HER2-positive breast cancer or triple-negative b...


...ocrine Therapy For ER Receptor-positive HER...

...ncotype DX, EndoPredict, Prosigna, Ki67, or IHC4...

...on 1.23If a patient has node-negative b...

...CI

....24If a patient has node-negative o...

...dation 1.25If a patient has node-po...

...cal Treatment Score post-5 Years (CTS5)...

...1.26If a patient is postmenopausal and had in...


...ve Breast Cancer or TNBC...

...doPredict, MammaPrint, BCI, Prosig...

...n 1.27If a patient has HER2-positive breast canc...


...erging Biomarkers...

...-Infiltrating Lymphocytes (TILs)...

...on 1.28If a patient has node-negative or node-p...

PD-L1 Testin...

Recommendation 1.29If a patient has...

...ulating Tumor Cells (CT...

...mmendation 1.30If a patient has node...

...ting Tumor DNA (ctDNA)...

...ndation 1.31If a patient has node-negative o...


...east Cancer Biomarkers to Guide Adjuvant...


...lgorithm on Biomarkers to Guide Decisions on...


...assification of Patients According to...


...ASCO believes that cancer clinical trials are vit...